Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H23BrFN5O2 |
| Molecular Weight | 488.353 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(C[C@H]2COC3=CC4=NC=NC(NC5=CC=CC(Br)=C5F)=C4C=C3O2)CC1
InChI
InChIKey=PHQOQKGDQRKQNK-AWEZNQCLSA-N
InChI=1S/C22H23BrFN5O2/c1-28-5-7-29(8-6-28)11-14-12-30-19-10-18-15(9-20(19)31-14)22(26-13-25-18)27-17-4-2-3-16(23)21(17)24/h2-4,9-10,13-14H,5-8,11-12H2,1H3,(H,25,26,27)/t14-/m0/s1
| Molecular Formula | C22H23BrFN5O2 |
| Molecular Weight | 488.353 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 12:05:05 GMT 2025
by
admin
on
Wed Apr 02 12:05:05 GMT 2025
|
| Record UNII |
B68F5P9PB7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
944323
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B68F5P9PB7
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY | |||
|
C187232
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY | |||
|
162532892
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY | |||
|
2490431-16-6
Created by
admin on Wed Apr 02 12:05:05 GMT 2025 , Edited by admin on Wed Apr 02 12:05:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
PRECLINICAL
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Treatment of malignant glioma, which includes glioblastoma (GBM).
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| BRAIN/PLASMA RATIO | PHARMACOKINETIC |
|
|
|||